header logo image


Page 279«..1020..278279280281..290300..»

Gear up for the change! Unity Biotechnology Inc. (UBX) has hit the volume of 830077 – The InvestChronicle

December 4th, 2020 12:01 am

Lets start up with the current stock price of Unity Biotechnology Inc. (UBX), which is $5.97 to be very precise. The Stock rose vividly during the last session to $6.55 after opening rate of $5.74 while the lowest price it went was recorded $5.74 before closing at $6.36.

Recently in News on November 4, 2020, UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates. UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2020. You can read further details here

My Next COVID-19 Stock Alert Poised For Triple Digit Moves

Get Ready for my next COVID-19 stock idea.I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alerts first before the crowd.

>> Sign Up Now to Get Name & Ticker Symbolof Next Triple-Digit Gainer

Sponsored

Unity Biotechnology Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $15.44 on 08/10/20, with the lowest value was $2.72 for the same time period, recorded on 08/24/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Unity Biotechnology Inc. shares are logging -61.37% during the 52-week period from high price, and 119.30% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $2.72 and $15.44.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 830077 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Unity Biotechnology Inc. (UBX) recorded performance in the market was -11.79%, having the revenues showcasing 110.60% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 298.98M, as it employees total of 76 workers.

During the last month, 5 analysts gave the Unity Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.37, with a change in the price was noted -1.83. In a similar fashion, Unity Biotechnology Inc. posted a movement of -23.22% for the period of last 100 days, recording 1,269,373 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for UBX is recording 0.25 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.25.

Raw Stochastic average of Unity Biotechnology Inc. in the period of last 50 days is set at 80.52%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 76.41%. In the last 20 days, the companys Stochastic %K was 88.45% and its Stochastic %D was recorded 90.89%.

Lets take a glance in the erstwhile performances of Unity Biotechnology Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -11.79%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -32.20%, alongside a downfall of -12.88% for the period of the last 12 months. The shares increased approximately by 34.46% in the 7-day charts and went down by 59.80% in the period of the last 30 days. Common stock shares were driven by 110.60% during last recorded quarter.

See the original post:
Gear up for the change! Unity Biotechnology Inc. (UBX) has hit the volume of 830077 - The InvestChronicle

Read More...

Update on the latest sports – Newscenter1.tv

December 3rd, 2020 11:59 pm

NFL-NEWS

Goodell: NFL committed to finishing regular season on time

UNDATED (AP) NFL Commissioner Roger Goodell says the league remains committed to finishing the regular season as scheduled. Goodell also said on a conference call that while the NFL is considering a bubble format for the playoffs, although it wouldnt necessarily resemble what the NHL and NBA used successfully in completing their seasons.

The leagues chief football administrative officer, stressed that the NFL plans to finish the schedule within the original 17-week format.

In other NFL news:

Quarterbacks Drew Lock and Brett Rypien (RIH-pihn) returned to the Denver Broncos practice Wednesday after coming off the reserve/COVID-19 list while the Broncos isolated practice squad veteran Blake Bortles. All three quarterbacks were banned from last weekends game against the New Orleans Saints after failing to wear their masks around quarterback Jeff Driskel, who tested positive for the coronavirus on Thanksgiving. The Broncos returned rookie receiver Kendall Hinton to their practice squad. Hinton filled in for Lock on Sunday when he completed just one of nine passes and was intercepted twice. Lock praised Hinton for his emergency QB work Sunday.

The Green Bay Packers have activated rookie linebacker Krys Barnes from the reserve/COVID-19 list. Barnes has missed three straight games since getting placed on that list Nov. 6. The undrafted free agent from UCLA has 48 tackles.

The Cleveland Browns are dealing with another COVID-19 case after an unidentified staff member tested positive. The team closed its facility Wednesday to conduct contact tracing, which has become routine the past two weeks because of several other positive tests. The Browns are expected to practice indoors after heavy snow in the Cleveland area. They activated star defensive end Myles Garrett from the reserve/COVID-19 list on Tuesday and expect him to practice as they get ready to play at Tennessee on Sunday. Garrett missed two games after becoming infected.

Quarterback Mike Glennon is getting another start for the Jacksonville Jaguars even though Gardner Minshew is healthy. Coach Doug Marrone says Minshew has been cleared to practice in full after recovering from a sprained thumb on his throwing hand, but hes sticking with Glennon at Minnesota on Sunday. Glennon was solid in his first start since Week 4 of the 2017 season.

The Buffalo Bills are in position to get healthier for their stretch run with linebackers Matt Milano and Tyrel Dodson designated to return to practice after spending time on injured reserve. Buffalo also signed receiver Jake Kumerow off its practice squad, adding depth at the position with starter John Brown placed on IR due to an ankle injury last weekend.

The Detroit Lions put cornerback Desmond Trufant and defensive tackle Danny Shelton on injured reserve. The Lions also activated tight end Hunter Bryant from IR and signed defensive tackle Kevin Strong to the active roster from the practice squad and signed cornerback Alex Myres to the practice squad. Defensive end Julian Okwara and cornerback Darryl Roberts returned to practice from IR today. Detroit plays at Chicago this weekend in its first game since coach Matt Patricia was fired.

Anthony Lynn and the Los Angeles Chargers has publicly acknowledged it would take a miracle for his team to make the playoffs even if the Chargers win their final five games to finish 8-8. The Chargers go into Sundays game against New England four games behind Miami and Indianapolis for the final AFC spots.

Harvey Langi is thriving while starting at inside linebacker for the New York Jets. He has 29 tackles since moving into the lineup in Week 9 following the trade of Avery Williamson to Pittsburgh. Langi has become a fan favorite with the Jets for his high energy approach on defense.

A 12th former NFL player has pleaded guilty in Kentucky in a multimillion-dollar health-fraud scheme. Former Washington Football Team and San Francisco 49ers cornerback Carlos Rogers pleaded guilty Monday to one charge of conspiring to defraud a program set up to reimburse former players for out-of-pocket medical expenses.

COLLEGE BASKETBALL-SCHEDULE

Coleman, No. 17 Texas beat No. 14 UNC 69-67 for Maui title

ASHEVILLE, N.C. (AP) Matt Coleman III hit a stepback jumper with 0.1 seconds left to help No. 17 Texas beat No. 14 North Carolina 69-67 for the championship of the relocated Maui Invitational. Coleman finished with 22 points and was the tournaments most valuable player for the Longhorns. Texas won despite blowing a 16-point first-half lead and falling behind in the final 2 1/2 minutes. Garrison Brooks had 18 points to lead the Tar Heels despite playing through an ankle injury that had him spend time in the locker room at least twice.

VIRUS OUTBREAK-COLLEGE SPORTS

Virus continues to scramble college sports schedules

UNDATED (AP) Michigan athletic director Warde Manuel is rebuking any suggestion the Wolverines would try to avoid facing rival Ohio State in the regular-season finale. He calls the notion ridiculous and infuriating. Michigans game against Maryland this weekend was canceled after the Wolverines suspended team activities because of an outbreak of COVID-19. It could also threaten their rivalry game against Ohio State on Dec. 12. A cancellation there could leave the Buckeyes with not enough games to be eligible for the Big Ten championship game.

In other virus-related college sports news:

The Las Vegas Bowl has been canceled because of the ongoing coronavirus pandemic. Executive director John Saccenti says it was a difficult decision but the right one considering the game was founded to help drive tourism to the gambling mecca. The decision comes as Nevada state officials ordered a statewide pause that includes smaller public and private gatherings. The game was slated to be the first bowl game played in Allegiant Stadium and was to feature a new matchup between the Pac-12 Conference and Southeastern Conference as part of a rotating cycle that also includes the Big Ten.

Mississippi has suspended team activities in football during the Rebels open date after COVID-19 test results came back. He says the team would wait on results from Wednesdays retesting. The Rebels are off this week after the SEC shuffled the schedule. They still have games to make up against Texas A&M and LSU.

Middle Tennessee has canceled Sundays home football game with UAB because of COVID-19, contact tracing and injuries inside the Blue Raiders program. Its the second straight week Middle Tennessee has canceled a game. Athletic director Chris Massaro says theyre down to 49 scholarship players and wouldve been forced to play some players coming off injuries.

Kent States football game at Miami of Ohio scheduled for Saturday has been canceled due to positive COVID-19 tests within the Golden Flashes program. The Mid-American Conference issued a statement saying the game has been declared a no contest. Its the second cancellation for Miami, which had its Nov. 17 game against Ohio wiped out.

George Mason has called off its mens basketball game at Maryland scheduled for Friday because of what the Virginia school says is a positive COVID-19 test during routine testing, which happens three times a week.

No. 17 Texas Tech has replaced a mens basketball game that was canceled because of COVID-19 concerns. The Red Raiders will now play Troy at home in a non-conference game Friday night.

No. 19 Richmonds mens basketball is pausing all activities and its game at College of Charleston on Wednesday night has been called off due to COVID-19 concerns within the Spiders program. Charleston said Tuesday it will look to reschedule with Richmond or find another opponent to make up the lost game.

College basketball is returning to Madison Square Garden this month for The Holiday Hoops Classic. In a matchup between the past two NCAA champions, Villanova and Virginia are scheduled to square off Dec. 19 in the heart of New York City. It will be the first college game at The Garden since the Big East Tournament was stopped at halftime of a March 12 quarterfinal between St. Johns and Creighton. Not long after that, the rest of the 2019-20 season was scuttled and the NCAA Tournament was canceled.

NBA SCHEDULE

Lakers-Clippers, Durant-Warriors set for NBA opening night

NEW YORK (AP) Kevin Durant is scheduled to make his Brooklyn debut against his former Golden State teammates before the Lakers begin their title defense in an all-Los Angeles matchup with the Clippers in the NBAs Dec. 22 opening-night doubleheader.

The Lakers will be back in action against the Dallas Mavericks on Dec. 25 as one of five games on the Christmas lineup.

The NBA announced the national TV schedule for the first three nights of the season on Wednesday. The complete schedule for the first half of the season, shortened to 72 games because of the coronavirus, will be announced Friday.

Elsewhere in the NBA:

LeBron James has agreed to a contract extension with the Los Angeles Lakers. James previous deal ran only through the upcoming season with a player option for 2021-22, allowing him to leave the NBA champions as a free agent next summer if he chose. Instead, the four-time NBA champion committed to play through his 20th NBA season with the Lakers, his third club after title-winning runs in Cleveland and Miami.

Zion Williamson expects to unleash a version of himself that is healthier, more demonstrative and less restrained in his second NBA season with the New Orleans Pelicans. Williamson says Year 1 was a lot mentally and physically for him. But he says he needed that experience. Williamson also says he was not able to showcase a lot of his game last season because he was more focused on fitting in with the team and trying not to be the rookie to mess up. Williamson says he now feels great physically and understands much more about playing in the NBA.

Boston Celtics point guard Kemba Walker says his left knee has responded well to a stem cell injection that is expected to keep him out until at least January. Walker says he wasnt himself during the playoffs, when the Celtics reached the Eastern Conference finals. He says he wont rush back to play until he is back at his best.

MLB-NEWS

Royals sign lefty starter Mike Minor to 2 year, $18M deal

UNDATED (AP) Left-hander Mike Minor and the Kansas City Royals have finalized an $18 million, two-year deal, reuniting the 32-year-old starter with the club that helped him revive his career.

The contract includes a club option for 2023 for $13 million with a $1 million buyout. The 32-year-old Minor split 2020 between the Texas Rangers and Oakland Athletics, going 1-6 with a 5.56 ERA and diminished velocity after posting the best numbers of his career a year earlier.

In other MLB news:

The Minnesota Twins have agreed to a $2.2 million, one-year contract with reliever Tyler Duffey, according to a person with knowledge of the deal. Duffey was one of seven Twins players eligible for salary arbitration for the 2021 season, joining left fielder Eddie Rosario, starting pitcher Jos Berros, center fielder Byron Buxton, closer Taylor Rogers, catcher Mitch Garver and relief pitcher Matt Wisler.

The Chicago White Sox have declined to offer 2021 contracts to right fielder Nomar Mazara and pitcher Carlos Rodn, sending the pair into free agency. Meanwhile, Jace Fry gets a one-year deal worth $862,500.

The most recent first-round draft pick of the Tampa Bay Rays has undergone surgery on his right shoulder. Pitcher Nick Bitsko had the operation Tuesday to repair a labrum issue. The 18-year-old from Pennsylvania has displayed a fastball that reached just under 100 mph. The Rays have not ruled out Bitsko being able to pitch at some point during the 2021 season.

The Milwaukee Brewers are taking a step to shore up their catching situation after getting little production from that position last season. A person familiar with the situation tells The Associated Press the Brewers have agreed to terms on a major league deal with Luke Maile. Maile was with the Pittsburgh Pirates last season but missed the entire abbreviated season due to a fractured right index finger.

The Chicago Cubs have claimed reliever Robert Stock off waivers from the Boston Red Sox. Stock appeared in 10 games with Boston during the pandemic-shortened season, going 0-1 with a 4.73 ERA. The 31-year-old right-hander was designated for assignment last week.

NHL-NEWS

Bettman: NHL players have to decide to pay now or later

UNDATED (AP) NHL Commissioner Gary Bettman says players are likely going to have to pay one way or another to make up for lost league revenue whenever the 2020-21 season gets underway. Bettman says the pandemic will affect revenue and that is expected to affect the 50-50 revenue-sharing split between owners and players.

Players will have to bear the brunt of any shortfall to owners. Bettman says the question is whether players should defer a higher percentage of their salaries now or face the potential of having the salary cap stay flat for several years.

OBIT-RAFER JOHNSON

Rafer Johnson, 1960 Olympic decathlon champion, dies at 86

LOS ANGELES (AP) Rafer Johnson, who won the decathlon at the 1960 Rome Olympics and helped subdue Robert F. Kennedys assassin in 1968, died Wednesday. He was 86.

He died at his home in the Sherman Oaks section of Los Angeles, according to family friend Michael Roth. No cause of death was announced.

Johnson was among the worlds greatest athletes from 1955 through his Olympic triumph in 1960, winning a national decathlon championship in 1956 and a silver medal at the Melbourne Olympics that same year.

On June 5, 1968, Johnson was working on Kennedys presidential campaign when the Democratic candidate was shot in the kitchen of the Ambassador Hotel in Los Angeles. Johnson joined former NFL star Rosey Grier and journalist George Plimpton in apprehending Sirhan Sirhan moments after he shot Kennedy, who died the next day.

More:
Update on the latest sports - Newscenter1.tv

Read More...

Update on the latest sports-UPDATED – Newscenter1.tv

December 3rd, 2020 11:59 pm

NFL-SCHEDULE

Steelers overcome rust, short-handed Ravens to move to 11-0

PITTSBURGH (AP) Ben Roethlisberger threw for 266 yards and a fourth-quarter touchdown to JuJu Smith-Schuster and the Steelers improved to 11-0 with a disjointed 19-14 win over the undermanned Baltimore Ravens.

The game was postponed three times while the Ravens dealt with a COVID-19 outbreak that forced Baltimore to take the field minus star quarterback Lamar Jackson among others.

The extended layoff led to some ugly football in a game filled with turnovers and inconsistent play. Still, the Steelers survived behind just enough offense and a defense that forced a pair of turnovers and had three sacks.

NFL-NEWS

Goodell: NFL committed to finishing regular season on time

UNDATED (AP) NFL Commissioner Roger Goodell says the league remains committed to finishing the regular season as scheduled. Goodell also said on a conference call that while the NFL is considering a bubble format for the playoffs, although it wouldnt necessarily resemble what the NHL and NBA used successfully in completing their seasons.

The leagues chief football administrative officer, stressed that the NFL plans to finish the schedule within the original 17-week format.

In other NFL news:

Quarterbacks Drew Lock and Brett Rypien (RIH-pihn) returned to the Denver Broncos practice Wednesday after coming off the reserve/COVID-19 list while the Broncos isolated practice squad veteran Blake Bortles. All three quarterbacks were banned from last weekends game against the New Orleans Saints after failing to wear their masks around quarterback Jeff Driskel, who tested positive for the coronavirus on Thanksgiving. The Broncos returned rookie receiver Kendall Hinton to their practice squad. Hinton filled in for Lock on Sunday when he completed just one of nine passes and was intercepted twice. Lock praised Hinton for his emergency QB work Sunday.

The Green Bay Packers have activated rookie linebacker Krys Barnes from the reserve/COVID-19 list. Barnes has missed three straight games since getting placed on that list Nov. 6. The undrafted free agent from UCLA has 48 tackles.

The Cleveland Browns are dealing with another COVID-19 case after an unidentified staff member tested positive. The team closed its facility Wednesday to conduct contact tracing, which has become routine the past two weeks because of several other positive tests. The Browns are expected to practice indoors after heavy snow in the Cleveland area. They activated star defensive end Myles Garrett from the reserve/COVID-19 list on Tuesday and expect him to practice as they get ready to play at Tennessee on Sunday. Garrett missed two games after becoming infected.

Quarterback Mike Glennon is getting another start for the Jacksonville Jaguars even though Gardner Minshew is healthy. Coach Doug Marrone says Minshew has been cleared to practice in full after recovering from a sprained thumb on his throwing hand, but hes sticking with Glennon at Minnesota on Sunday. Glennon was solid in his first start since Week 4 of the 2017 season.

The Buffalo Bills are in position to get healthier for their stretch run with linebackers Matt Milano and Tyrel Dodson designated to return to practice after spending time on injured reserve. Buffalo also signed receiver Jake Kumerow off its practice squad, adding depth at the position with starter John Brown placed on IR due to an ankle injury last weekend.

The Detroit Lions put cornerback Desmond Trufant and defensive tackle Danny Shelton on injured reserve. The Lions also activated tight end Hunter Bryant from IR and signed defensive tackle Kevin Strong to the active roster from the practice squad and signed cornerback Alex Myres to the practice squad. Defensive end Julian Okwara and cornerback Darryl Roberts returned to practice from IR today. Detroit plays at Chicago this weekend in its first game since coach Matt Patricia was fired.

Anthony Lynn and the Los Angeles Chargers has publicly acknowledged it would take a miracle for his team to make the playoffs even if the Chargers win their final five games to finish 8-8. The Chargers go into Sundays game against New England four games behind Miami and Indianapolis for the final AFC spots.

Harvey Langi is thriving while starting at inside linebacker for the New York Jets. He has 29 tackles since moving into the lineup in Week 9 following the trade of Avery Williamson to Pittsburgh. Langi has become a fan favorite with the Jets for his high energy approach on defense.

A 12th former NFL player has pleaded guilty in Kentucky in a multimillion-dollar health-fraud scheme. Former Washington Football Team and San Francisco 49ers cornerback Carlos Rogers pleaded guilty Monday to one charge of conspiring to defraud a program set up to reimburse former players for out-of-pocket medical expenses.

COLLEGE BASKETBALL-SCHEDULE

Coleman, No. 17 Texas beat No. 14 UNC 69-67 for Maui title

ASHEVILLE, N.C. (AP) Matt Coleman III hit a stepback jumper with 0.1 seconds left to help No. 17 Texas beat No. 14 North Carolina 69-67 for the championship of the relocated Maui Invitational. Coleman finished with 22 points and was the tournaments most valuable player for the Longhorns. Texas won despite blowing a 16-point first-half lead and falling behind in the final 2 1/2 minutes. Garrison Brooks had 18 points to lead the Tar Heels despite playing through an ankle injury that had him spend time in the locker room at least twice.

VIRUS OUTBREAK-COLLEGE SPORTS

Virus continues to scramble college sports schedules

UNDATED (AP) Michigan athletic director Warde Manuel is rebuking any suggestion the Wolverines would try to avoid facing rival Ohio State in the regular-season finale. He calls the notion ridiculous and infuriating. Michigans game against Maryland this weekend was canceled after the Wolverines suspended team activities because of an outbreak of COVID-19. It could also threaten their rivalry game against Ohio State on Dec. 12. A cancellation there could leave the Buckeyes with not enough games to be eligible for the Big Ten championship game.

In other virus-related college sports news:

The Las Vegas Bowl has been canceled because of the ongoing coronavirus pandemic. Executive director John Saccenti says it was a difficult decision but the right one considering the game was founded to help drive tourism to the gambling mecca. The decision comes as Nevada state officials ordered a statewide pause that includes smaller public and private gatherings. The game was slated to be the first bowl game played in Allegiant Stadium and was to feature a new matchup between the Pac-12 Conference and Southeastern Conference as part of a rotating cycle that also includes the Big Ten.

Mississippi has suspended team activities in football during the Rebels open date after COVID-19 test results came back. He says the team would wait on results from Wednesdays retesting. The Rebels are off this week after the SEC shuffled the schedule. They still have games to make up against Texas A&M and LSU.

Middle Tennessee has canceled Sundays home football game with UAB because of COVID-19, contact tracing and injuries inside the Blue Raiders program. Its the second straight week Middle Tennessee has canceled a game. Athletic director Chris Massaro says theyre down to 49 scholarship players and wouldve been forced to play some players coming off injuries.

Kent States football game at Miami of Ohio scheduled for Saturday has been canceled due to positive COVID-19 tests within the Golden Flashes program. The Mid-American Conference issued a statement saying the game has been declared a no contest. Its the second cancellation for Miami, which had its Nov. 17 game against Ohio wiped out.

George Mason has called off its mens basketball game at Maryland scheduled for Friday because of what the Virginia school says is a positive COVID-19 test during routine testing, which happens three times a week.

No. 17 Texas Tech has replaced a mens basketball game that was canceled because of COVID-19 concerns. The Red Raiders will now play Troy at home in a non-conference game Friday night.

No. 19 Richmonds mens basketball is pausing all activities and its game at College of Charleston on Wednesday night has been called off due to COVID-19 concerns within the Spiders program. Charleston said Tuesday it will look to reschedule with Richmond or find another opponent to make up the lost game.

College basketball is returning to Madison Square Garden this month for The Holiday Hoops Classic. In a matchup between the past two NCAA champions, Villanova and Virginia are scheduled to square off Dec. 19 in the heart of New York City. It will be the first college game at The Garden since the Big East Tournament was stopped at halftime of a March 12 quarterfinal between St. Johns and Creighton. Not long after that, the rest of the 2019-20 season was scuttled and the NCAA Tournament was canceled.

NBA SCHEDULE

Lakers-Clippers, Durant-Warriors set for NBA opening night

NEW YORK (AP) Kevin Durant is scheduled to make his Brooklyn debut against his former Golden State teammates before the Lakers begin their title defense in an all-Los Angeles matchup with the Clippers in the NBAs Dec. 22 opening-night doubleheader.

The Lakers will be back in action against the Dallas Mavericks on Dec. 25 as one of five games on the Christmas lineup.

The NBA announced the national TV schedule for the first three nights of the season on Wednesday. The complete schedule for the first half of the season, shortened to 72 games because of the coronavirus, will be announced Friday.

Elsewhere in the NBA:

LeBron James has agreed to a contract extension with the Los Angeles Lakers. James previous deal ran only through the upcoming season with a player option for 2021-22, allowing him to leave the NBA champions as a free agent next summer if he chose. Instead, the four-time NBA champion committed to play through his 20th NBA season with the Lakers, his third club after title-winning runs in Cleveland and Miami.

Zion Williamson expects to unleash a version of himself that is healthier, more demonstrative and less restrained in his second NBA season with the New Orleans Pelicans. Williamson says Year 1 was a lot mentally and physically for him. But he says he needed that experience. Williamson also says he was not able to showcase a lot of his game last season because he was more focused on fitting in with the team and trying not to be the rookie to mess up. Williamson says he now feels great physically and understands much more about playing in the NBA.

Boston Celtics point guard Kemba Walker says his left knee has responded well to a stem cell injection that is expected to keep him out until at least January. Walker says he wasnt himself during the playoffs, when the Celtics reached the Eastern Conference finals. He says he wont rush back to play until he is back at his best.

MLB-NEWS

Royals sign lefty starter Mike Minor to 2 year, $18M deal

UNDATED (AP) Left-hander Mike Minor and the Kansas City Royals have finalized an $18 million, two-year deal, reuniting the 32-year-old starter with the club that helped him revive his career.

The contract includes a club option for 2023 for $13 million with a $1 million buyout. The 32-year-old Minor split 2020 between the Texas Rangers and Oakland Athletics, going 1-6 with a 5.56 ERA and diminished velocity after posting the best numbers of his career a year earlier.

In other MLB news:

The Minnesota Twins have agreed to a $2.2 million, one-year contract with reliever Tyler Duffey, according to a person with knowledge of the deal. Duffey was one of seven Twins players eligible for salary arbitration for the 2021 season, joining left fielder Eddie Rosario, starting pitcher Jos Berros, center fielder Byron Buxton, closer Taylor Rogers, catcher Mitch Garver and relief pitcher Matt Wisler.

The Chicago White Sox have declined to offer 2021 contracts to right fielder Nomar Mazara and pitcher Carlos Rodn, sending the pair into free agency. Meanwhile, Jace Fry gets a one-year deal worth $862,500.

The most recent first-round draft pick of the Tampa Bay Rays has undergone surgery on his right shoulder. Pitcher Nick Bitsko had the operation Tuesday to repair a labrum issue. The 18-year-old from Pennsylvania has displayed a fastball that reached just under 100 mph. The Rays have not ruled out Bitsko being able to pitch at some point during the 2021 season.

The Milwaukee Brewers are taking a step to shore up their catching situation after getting little production from that position last season. A person familiar with the situation tells The Associated Press the Brewers have agreed to terms on a major league deal with Luke Maile. Maile was with the Pittsburgh Pirates last season but missed the entire abbreviated season due to a fractured right index finger.

The Chicago Cubs have claimed reliever Robert Stock off waivers from the Boston Red Sox. Stock appeared in 10 games with Boston during the pandemic-shortened season, going 0-1 with a 4.73 ERA. The 31-year-old right-hander was designated for assignment last week.

NHL-NEWS

Bettman: NHL players have to decide to pay now or later

UNDATED (AP) NHL Commissioner Gary Bettman says players are likely going to have to pay one way or another to make up for lost league revenue whenever the 2020-21 season gets underway. Bettman says the pandemic will affect revenue and that is expected to affect the 50-50 revenue-sharing split between owners and players.

Players will have to bear the brunt of any shortfall to owners. Bettman says the question is whether players should defer a higher percentage of their salaries now or face the potential of having the salary cap stay flat for several years.

OBIT-RAFER JOHNSON

Rafer Johnson, 1960 Olympic decathlon champion, dies at 86

LOS ANGELES (AP) Rafer Johnson, who won the decathlon at the 1960 Rome Olympics and helped subdue Robert F. Kennedys assassin in 1968, died Wednesday. He was 86.

He died at his home in the Sherman Oaks section of Los Angeles, according to family friend Michael Roth. No cause of death was announced.

Johnson was among the worlds greatest athletes from 1955 through his Olympic triumph in 1960, winning a national decathlon championship in 1956 and a silver medal at the Melbourne Olympics that same year.

On June 5, 1968, Johnson was working on Kennedys presidential campaign when the Democratic candidate was shot in the kitchen of the Ambassador Hotel in Los Angeles. Johnson joined former NFL star Rosey Grier and journalist George Plimpton in apprehending Sirhan Sirhan moments after he shot Kennedy, who died the next day.

The rest is here:
Update on the latest sports-UPDATED - Newscenter1.tv

Read More...

Treating neuropathy: Which medication is best? – Harvard Health Blog – Harvard Health

December 3rd, 2020 11:58 pm

Imagine experiencing burning, tingling, and numbness in your legs day in and day out, getting worse over time and your doctors cant find a reason for it.

Thats the situation for millions of people who suffer from idiopathic sensory polyneuropathy. The term idiopathic means that no cause can be identified; sensory refers to the type of nerve, in this case those carrying nerve signals such as pain or temperature; poly means many and neuropathy means nerve disease. So, this is a condition of unknown cause that damages multiple nerves; the most affected nerves tend to be those that provide sensation to the legs and feet.

Sometimes other terms are used, including cryptogenic neuropathy or chronic polyneuropathy of undetermined cause. For some people, neuropathy is due to diabetes, alcohol abuse, medications, or other conditions. But in nearly half of all cases, sensory polyneuropathy is idiopathic.

Regardless of which name is used, the condition is frustrating, annoying, and sometimes debilitating. And without an identifiable and reversible cause, there is no cure. While a number of medications are commonly prescribed, its not clear which is most effective or safest. So, doctors generally recommend a period of trial and error. One medication after another is prescribed, until one is found that is effective and doesnt cause intolerable side effects.

Unfortunately, it can take many months or even longer to find a treatment that works. Doctors have little guidance to know which ones to start with. Thats why research comparing treatment options is so important and yet, precious little comparative research on treatments for idiopathic sensory polyneuropathy has been published.

Researchers publishing in JAMA Neurology describe the results of a unique trial in which 402 people with idiopathic sensory polyneuropathy were randomly assigned to one of four medications: duloxetine, mexiletine, nortriptyline, or pregabalin. After 12 weeks, each person rated their neuropathy symptoms on a scale from 1 to 10, noted any side effects, and reported whether they had quit taking the medication due to side effects, cost, or some other reason.

Though the trial is important and much needed, the results were disappointing.

This trial had a number of important limitations:

Direct comparisons of treatments for idiopathic sensory polyneuropathy which many simply call neuropathy are sorely needed, so this trial is important. Yet, the biggest take-home message of this research is that many current treatments arent very good.

Overall, nortriptyline and duloxetine appeared to outperform the other drugs in this trial, so they would be good choices to start with rather than pregabalin and mexiletine. But when the best treatments work well for only a quarter or less of patients, and nearly half quit treatment in the first 12 weeks, its clear that better, safer, and less expensive treatments are needed.

Perhaps we already have better treatments that werent part of this trial. Well need additional comparative research to know for sure.

Follow me on Twitter @RobShmerling

Go here to read the rest:
Treating neuropathy: Which medication is best? - Harvard Health Blog - Harvard Health

Read More...

Take your life back from the pain of neuropathy – KHOU.com

December 3rd, 2020 11:58 pm

Stop the debilitating symptoms of neuropathy with help from Advanced Nerve and Health Center

HOUSTON Call Advanced Nerve and Health Center now at 832-626-1260 or log on to NerveAndHealth.com.

The Advanced Nerve and Health Center has a limited time offer for Great Day Houston viewers. For $29, get a tele-health visit, an in-office consultation, a copy of Dr. Thai's "Healthy Diet to Heal Nerve Pain" book, and a diagnostic nerve test to see if they can help. This is a $249 value.

Advanced Nerve and Health Center is located at 8558 Katy Freeway, Suite 116, Houston, TX 77024.

The Advanced Nerve and Health Center treats the root cause of neuropathy and reverses the damage to the nerve. Dr. Bao Thai and Dr. Aliena Sohail shared more in the video above about their process and how it works. Patient Charlotte Leach-Kiel used to be in such extreme pain that it would wake her up at night. She said it felt like her body was being tasered. She knew she had to reach out to Advanced Nerve & Health Center so she could have a better quality of life. After treatments, she has seen improvement, feels so much better, and no longer wakes up in the middle of the night.

This content sponsored by Advanced Nerve and Health Center.

See original here:
Take your life back from the pain of neuropathy - KHOU.com

Read More...

Chemotherapy Induced Peripheral Neuropathy Treatment Market Global Growth, Opportunities, Industry Analysis & Forecast To 2027 – Murphy’s Hockey…

December 3rd, 2020 11:58 pm

The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=171696

The Global Chemotherapy Induced Peripheral Neuropathy Treatment Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Chemotherapy Induced Peripheral Neuropathy Treatment Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=171696

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market as:Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, by Regions

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, by ProductsCalcium Channel 2-delta LigandsAntidepressantsOpioidsOthers

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size & Share, ApplicationsPlatinum AgentsTaxanesVinca AlkaloidsOthers

Key PlayersAptinyx IncAsahi Kasei Pharma CorpRegenacy PharmaceuticalsMAKScientific LLCMetys Pharmaceuticals AGNemus Bioscience IncPledPharmaSova Pharmaceuticals IncDermaXon LLCImmune Pharmaceuticals IncKineta IncKrenitsky Pharmaceuticals IncPeriphaGenApexian PharmaWinSanTorSolasia Pharma K.K.

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=171696

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Read more here:
Chemotherapy Induced Peripheral Neuropathy Treatment Market Global Growth, Opportunities, Industry Analysis & Forecast To 2027 - Murphy's Hockey...

Read More...

Neuropathy Pain Treatment Market 2020 Determined By Manufacturing Summary, Business Profile And Estimate To 2026 – Khabar South Asia

December 3rd, 2020 11:58 pm

DataIntelo, a prominent market research firm, has published a detailed report on Global Neuropathy Pain Treatment Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Neuropathy Pain Treatment market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. DataIntelo has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://dataintelo.com/checkout/?reportId=43829

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Neuropathy Pain Treatment market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Request A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=43829

Market Segmentation

Some of the major companies that are covered in the report.

DepomedEli LillyEndo InternationalPfizerAllodynic TherapeuticsArbor Pharmaceuticals

Note: Additional companies

Based on the type, the market is segmented into

Calcium Channel Alpha 2-delta LigandsSerotonin-norepinephrine Reuptake InhibitorsOthers

Based on the application, the market is segregated into

Retail PharmaciesHospitalsOthers

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

DataIntelo provides yearly updates on the Neuropathy Pain Treatment market that assist the clients to stay ahead in the competitive space.

Why one should buy this Neuropathy Pain Treatment Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

DataIntelo bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Neuropathy Pain Treatment Market Overview

Neuropathy Pain Treatment Supply Chain Analysis

Neuropathy Pain Treatment Pricing Analysis

Global Neuropathy Pain Treatment Market Analysis and Forecast by Type

Global Neuropathy Pain Treatment Market Analysis and Forecast by Application

Global Neuropathy Pain Treatment Market Analysis and Forecast by Sales Channel

Global Neuropathy Pain Treatment Market Analysis and Forecast by Region

North America Neuropathy Pain Treatment Market Analysis and Forecast

Latin America Neuropathy Pain Treatment Market Analysis and Forecast

Europe Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Analysis and Forecast

Asia Pacific Neuropathy Pain Treatment Market Size and Volume Forecast by Application

Middle East & Africa Neuropathy Pain Treatment Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://dataintelo.com/enquiry-before-buying/?reportId=43829

About the Company

DataIntelo is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

View post:
Neuropathy Pain Treatment Market 2020 Determined By Manufacturing Summary, Business Profile And Estimate To 2026 - Khabar South Asia

Read More...

The Effectiveness of Dorsal Root Ganglion Neurostimulation for the Treatment of Chronic Pelvic Pain and Chronic Neuropathic Pain of the Lower…

December 3rd, 2020 11:58 pm

To evaluate the effectiveness of dorsal root ganglion neurostimulation for the treatment of refractory, focal pain in the pelvis and lower extremities.Systematic review.The primary outcome was 50% pain relief. Secondary outcomes were physical function, mood, quality of life, opioid usage, and complications.One pragmatic randomized controlled trial, four prospective cohort studies, and eight case series met the inclusion criteria. A worst-case scenario analysis from the randomized controlled trial reported 50% pain relief in 74% of patients with dorsal root ganglion neurostimulation vs. 51% of patients who experienced at least 50% relief with spinal cord stimulation at 3 months. Cohort data success rates ranged from 43% to 83% at 6 months and 27% to 100% at >6 months. Significant improvements were also reported in the secondary outcomes assessed, including mood, quality of life, opioid usage, and health care utilization, though a lack of available quantitative data limits further statistical analysis. Complication rates vary, though the only randomized controlled trial reported a higher rate of adverse events than that seen with traditional neurostimulation.In accordance with the Grades of Recommendation, Assessment, Development, and Evaluation system, low-quality evidence supports dorsal root ganglion neurostimulation as a more effective treatment than traditional neurostimulation for pain and dysfunction associated with complex regional pain syndrome or causalgia. Very low-quality evidence supports dorsal root ganglion neurostimulation for the treatment of chronic pelvic pain, chronic neuropathic groin pain, phantom limb pain, chronic neuropathic pain of the trunk and/or limbs, and diabetic neuropathy. The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PubMed

Read more:
The Effectiveness of Dorsal Root Ganglion Neurostimulation for the Treatment of Chronic Pelvic Pain and Chronic Neuropathic Pain of the Lower...

Read More...

How Cold Weather Affects Cancer Patients – OncoZine

December 3rd, 2020 11:58 pm

Winter can be hard for many people, but for cancer patients, slippery streets, and cold weather are more than a hazard, they can also be a health risk. Learn how cold weather affects cancer patients and how they can stay safe during the winter.

HypothermiaHypothermia is a condition where the human body begins to lose heat faster than it can produce it, causing the body temperature to become dangerously low. Side effects of cancer treatment, such as fatigue, dehydration, and anemia, can make patients more susceptible to hypothermia.

FrostbiteSome treatments can cause peripheral neuropathy, which carries numbness in the extremities as a potential side effect. Patients who have peripheral neuropathy are more likely to get frostbite since they cant feel how cold their fingers and hands are in cold weather.

FallsPatients can have a higher risk of fracture if they are receiving treatments that affect bone density. Cancer patients need to be especially careful if they have thrombocytopenia, a condition associated with blood cancers that cause low platelet counts. Since platelets help blood clot, a low count can mean that bruising or serious bleeding can happen when injured.

Patients who have numbness in their feet (neuropathy) are also more prone to falls.

FluCancer therapy may weaken patients immune systems. It is necessary that they get their flu shot since they dont have enough white blood cells to fight infections. This is why cancer patients have a higher chance of having complications from the flu than a healthy person.

Tips to Stay SafeFollow these tips to protect your health or a loved one in winter and stay safe:

If youd rather avoid winter and the risks it carries for cancer patients, you can always consider health tourism. Its the practice of traveling to a popular tourist destination with the purpose of receiving therapeutic treatment. For example, Florida has mild, pleasant winters, which make it an ideal location for health tourism!

Winter wont last forever, even if you sometimes feel that way, so celebrate each sunny day!

More than a thousand men and women diagnosed with cancer each year turn to our trusted team of cancer specialists at Tampa Bay Radiation Oncology. We encourage you to call us, ask us a question, or consult with us to get a second opinion so you, too, can experience the difference.

Featured image: Winter. Photo courtesy: 2020 Pixabay/Ina Hoekstra (Heerenveen, The Netherlands)

Read more from the original source:
How Cold Weather Affects Cancer Patients - OncoZine

Read More...

Diabetic Peripheral Neuropathy Treatment Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 – The Haitian-Caribbean News Network

December 3rd, 2020 11:58 pm

New Jersey, United States: Market Research Intellect has added a new report to its huge database of research reports, entitled Diabetic Peripheral Neuropathy Treatment Market Size and Forecast to 2027. The report offers a comprehensive assessment of the market including insights, historical data, facts, and industry-validated market data. It also covers the projections using appropriate approximations and methods.

Diabetic Peripheral Neuropathy Treatment Market Overview

The Diabetic Peripheral Neuropathy Treatment Market Report provides comprehensive data on market dynamics, market trends, product growth rate, and price. The Diabetic Peripheral Neuropathy Treatment market report has various facts and statistics assuming the future predictions of the upcoming market participants. In addition, it offers business security taking into account sales, profit, market volume, demand and market supply ratio. The in-depth study provides vital information related to market growth, driving factors, major challenges, opportunities, and threats that will prove to be very helpful for market participants in making upcoming decisions.

Diabetic Peripheral Neuropathy Treatment Market: Competitive Landscape

The Diabetic Peripheral Neuropathy Treatment Market report consists of the Competitive Landscape section which provides a complete and in-depth analysis of current market trends, changing technologies, and enhancements that are of value to companies competing in the market. The report provides an overview of sales, demand, futuristic costs and data supply as well as a growth analysis in the forecast year. The key vendors in the market that are performing the analysis are also clearly presented in the report. Their development plans, their growth approaches, and their merger and acquisition plans are also identified. Information specific to a keyword in each of these regions is also provided. This report also discusses the submarkets of these regions and their growth prospects.

Prominent players operating in the market:

Diabetic Peripheral Neuropathy Treatment Market Segmentation

The report contains the market size with 2019 as the base year and an annual forecast up to 2027 in terms of sales (in million USD). For the forecast period mentioned above, estimates for all segments including type and application have been presented on a regional basis. We implemented a combination of top-down and bottom-up approaches to market size and analyzed key regional markets, dynamics and trends for different applications.

Diabetic Peripheral Neuropathy Treatment Market Segment by Type:

Diabetic Peripheral Neuropathy Treatment Market Segment by Application:

Diabetic Peripheral Neuropathy Treatment Market Regional overview:

In the report, experts analyze and forecast the Diabetic Peripheral Neuropathy Treatment market on a global as well as regional level. Taking into account all aspects of the market in terms of regions, the focus of the report is on North America, Europe, Asia Pacific, the Middle East and Africa, and South America. The prevailing trends and various opportunities in these regions are studied that can convince the growth of the market in the forecast period 2020 to 2027.

Reasons to Buy the Diabetic Peripheral Neuropathy Treatment Market Report:

Outlook analysis of the Diabetic Peripheral Neuropathy Treatment market sector with current trends and SWOT analysis. This study evaluates the dynamics, competition, industrial strategies and strategies of the emerging countries. This report has a comprehensive guide that provides market insights and detailed data on each market segment Market growth factors and risks are presented. More precise information provision on the Diabetic Peripheral Neuropathy Treatment market for different countries. Provide visions on factors influencing the growth of the market. Market segmentation analysis, including quantitative and qualitative research considering the impact of economic and non-economic aspects Comprehensive company profiles with product offerings, important financial information and the latest developments.

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Go here to see the original:
Diabetic Peripheral Neuropathy Treatment Market Size, Analysis, Growth, Trends, Outlook And Forecast By 2027 - The Haitian-Caribbean News Network

Read More...

Our Elderly In Isolation – And Response – The Chattanoogan

December 3rd, 2020 11:58 pm

As we attempt to protect our elderly population in this pandemic, this is what I see when I look through the window,

I look into the window as she awakens to the sound of business outside the door. I can tell that she is not sure who is outside her door. For that matter not sure of the day or time. Is it Wednesday, or Saturday. They all seem the same, day after day unchanging. Someone enters her room with very little conversation. No small talk, places her breakfast box on the tiny table by her chair. I see her say hello and smile at the woman, she just turns to leave. She slowly opens the Styrofoam box to find watery eggs and sausage and a cup of coffee. Her neuropathy wont allow her to open the sugar that she would love to have added to her coffee, but the woman is already gone. She tries to open it but finally puts it down and she just drinks it black. I watch her struggle to eat a few bites of the eggs, dropping them on her shirt. I think she finally figured it is morning. I see she has her TV on, but I know she cant hear much of the show as she is hearing impaired. I notice it has the closed caption on again. I guess she was trying to change the channel. She just cant use that remote and I cant get in to change it myself. She just sits listlessly staring ahead. Loneliness. Is what I see!

I knock on her window to get her attention. She finally looks up. She smiles, it makes me sad to see her happy just to see me through the window, but it is all I can do. Her hair is so disheveled. She would have never looked like this. She always had a standing appointment at the beauty shop weekly for a wash and style. But I guess it doesnt matter, she doesnt ever see her hair. She goes nowhere, only sitting in her room. Alone. I wave at her smiling, while fighting back tears. I hold up my phone to motion that I am going to call her room. I can hear it ringing. I watch her slowly reach for the phone. It continues to ring. Again her neuropathy slows her so much my call is forwarded to voice mail. I call back but now get an instant message. She has not ended the previous call. I finally call the facility and ask someone to please go to her room and help her answer the phone. She smiles as she hears my voice. Why cant these phones be like they used to be? Why cant I just answer it when someone calls me so I can talk to them? Can you please find me a phone like I used to have? Why do I have to push buttons? I cant remember which buttons to push. I just cant use this phone.

Another person with face covered, enters the room, hands her some pills and a sip of water. They are quickly gone. Alone again. She asks if I can just come in for a minute, she has something she wants to tell me. I try to explain that I cant come in at all. I would love to, but I am not allowed. I can only watch from outside the window. She tries to tell me something about last night, but her story is hard to follow. She was never like this, always so lucid with organized thought. This is all changing as I watch from outside the window. She again asks if I can get an appointment to see her. I feel like she thinks she is forgotten; the loneliness is overwhelming. She cannot understand why I dont visit.

I see her plant in the window sill, it needs watering. I tell her the plant needs a drink. But I know she cant water it and the people here are too busy she says. We talk about her breakfast, and I tell her I brought her a few goodies they will deliver to her room. She smiles. I finally tell her that Im leaving as it is cold outside. The smile fades and she says again can you come in for just a minute?

This is what I see from the window! This is one visit at her long term care facility. These visits are increasingly painful to watch and be a part of. The longer she is kept from her family, the worse she gets cognitively and physically. I see the sadness. I see the decline in her health through this window. I know there are others seeing the same as they look through their loved ones windows. The only thing these precious people have done wrong is get old. Now they are forced to live out their last days all alone. I understand we are trying to protect the frail and elderly, but is that really what we are doing?

Teresa Peers

* * *

Amen to Teresa Peers! You are not alone in this fight. I know all the facilities are doing their best to keep people safe, but at what cost?

I think many would choose to take a chance on the virus versus the isolation.

From one caregiver to another, I hear you.

Jeannie Hixon

See the article here:
Our Elderly In Isolation - And Response - The Chattanoogan

Read More...

Once-Per-Week Selinexor Triplet Appears Effective in Patients With Multiple Myeloma – Targeted Oncology

December 3rd, 2020 11:58 pm

A once-per-week selinexor (Xpovio), bortezomib (Velcade), plus dexamethasone treatment strategy appeared effective and convenient as treatment of patients with multiple myeloma who received at least 1 to 3 prior lines of therapy, according to findings from the phase 3, randomized, open-label BOSTON trial.

The study was conducted across 123 sites in 21 countries, and patients were randomized 1:1 to 1 of 2 arms; patients received selinexor 100 mg once per week, bortezomib 1.3 mg/m2 once per week, and dexamethasone 20 mg twice per week, or in the second arm, patients were treated with bortezomib 1.3 mg/m2twice per week for the first 24 weeks and once per week thereafter and dexamethasone 20 mg 4 times per week for the first 24 weeks and twice per week thereafter.

The primary end point of the study is progression-free survival (PFS), and secondary end points included objective response rate (ORR), overall survival (OS), and duration of response (DOR), as well as PFS and ORR in patients who crossed over from the control arm, PFS on subsequent line of therapy, time to next anti-multiple myeloma treatment, time to response, incidence of grade 2 or higher peripheral neuropathy events, and patient-reported peripheral neuropathy. Safety and tolerability were also reviewed as additional secondary end points.

The median age of patients in the experimental arm was 66 years (range, 59-72) compared with 67 years (range, 61-74) in the control arm, and the majority of patients were male in both arms (59% and 56%, respectively). Among patients randomized to the triplet arm (n = 195), 54% had an ECOG performance status of 1, 35% 0, and 10% 2, compared with 55%, 37%, and 8% in the control arm, which included 207 patients total. Most patients (51%) had received 1 prior line of therapy in the experimental arm versus 48% in the control, while 33% and 31% had 2 prior lines, and 16% and 21% had 3 prior lines, respectively.

Overall, the PFS was significantly longer with the triplet regimen compared with bortezomib and dexamethasone alone. The median PFS was 13.93 months (95% CI, 11.73-not evaluable [NE]) in the experimental arm versus 9.46 months (95% CI, 8.11-10.78) in the control arm (HR, 0.70; 95% CI, 0.53-0.93; P=.0075).

The ORR was significantly higher with the once-per-week regimen at 76.4% (95% CI, 69.8-82.2) compared with 62.3% (95% CI, 55.3-68.9) in the control arm (OR, 1.96; 95% CI, 1.3-3.1; P =.0012). In the triplet arm, the proportion of patients with a very good partial response or was 44.6% (95% CI, 37.5-51.9) compared with 32.4% (95% CI, 26.0-39.2) in the bortezomib plus dexamethasone arm (OR, 1.66; 95% CI, 1.1-2.5; P =.0082). The proportion of patients with stable disease or progressive disease as their best response was also lower in the triplet arm at 13.3% (95% CI, 8.9-18.9) compared with 24.2% in the control arm (95% CI, 18.5-30.6).

The median time to first response of a partial response or better was 1.1 months (interquartile range [IQR], 0.8-1.6) in the triplet arm versus 1.4 months (IQR, 0.8-1.6) in the control arm. The median duration of response was longer with the once-per-week regimen at 20.3 months (95% CI, 12.5-NE) compared with 12.9 months (95% CI, 9.3-15.8) in the control (HR, 0.81; 95% CI, 0.56-1.17; P =.1364). The median time to next anti-myeloma therapy was longer in the triplet arm as well at 10.8 months (95% CI, 9.8-13.4) versus 0.66 (95% CI, 0.50-0.86) in the control (P =.0012).

Overall, 47 patients (24%) died in the experimental arm compared with 62 (30%) in the control arm. The median OS was not reached after a median follow-up of 17.3 months in the triplet arm (IQR, 12.9-20.3) versus 25 months (95% CI, 23.5-NE) after 17.5 months follow-up in the experimental arm (HR, 0.84; 95% CI, 0.57-1.23; P =.1852).

In the safety analysis, 195 patients from the triplet arm and 204 from the doublet arm were included. The most common treatment-emergent adverse events (AEs) of grade 3/4 included thrombocytopenia (39% vs 17%), anemia (16% vs 10%, pneumonia (12% vs 10%), and fatigue (13% vs 1%), and these all occurred in higher incidences in the triplet arm compared with the control, respectively.

Treatment was discontinued in 41 (21%) of patients in the experimental arm versus 32 (16%) in the control arm due to treatment-emergent AEs. The most common reasons for treatment discontinuation included peripheral neuropathy (5%), fatigue (4%), nausea (3%), vomiting (2%), decreased appetite (2%), and thrombocytopenia (2%) in the triplet arm, and the most common reason in the control arm was peripheral neuropathy (7%).

The median time to treatment discontinuation was 194 days (IQR, 100-332) in the experimental arm versus 184 (IQR, 106-276) in the control arm, and among all patients who had discontinued, 19 (46%) in the once-per-week arm and 16 (50%) in the bortezomib and dexamethasone arm were over the age of 70 years.

Dose modifications were common in the triplet arm, occurring in 173 (89%) of patients compared with 156 (76%). Most of the side effects that were associated with selinexor were reversible and were mitigated with standard supportive care.

Serious AEs occurred in 101 (52%) of patients in the once-per-week arm versus 77 (38%) in the control arm, and the most frequent serious AE was pneumonia, occurring in 12% of each arm.

Overall, this study demonstrated a significant increase in PFS for patients previously treated with multiple myeloma when treated with the triplet versus the control arm of bortezomib with dexamethasone. The benefit was observed across subgroups, and the improved efficacy was particularly notable in that it was achieved during the first 24 weeks of therapy, according to the study authors.

Reference

Grosicki S, Simonova M, Spicka I, et al.Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.Lancet. 2020;396(10262):P1563-1573. doi: 10.1016/S0140-6736(20)32292-3

More here:
Once-Per-Week Selinexor Triplet Appears Effective in Patients With Multiple Myeloma - Targeted Oncology

Read More...

The Ischemic Optic Neuropathy Treatment Market to remain unfazed by the Global Recession – Khabar South Asia

December 3rd, 2020 11:58 pm

Ischemic optic neuropathy is caused due to a small vessel infraction of the optic nerve and is a major cause of blindness or impaired vision among the inflicted. There are two types of ischemic optic neuropathies viz. anterior ischemic optic neuropathy and posterior or non-anterior ischemic optic neuropathy. Anterior ischemic optic neuropathy is caused by the inflammation of arteries supplying blood to the optic nerve whereas posterior or non-anterior ischemic optic neuropathy is caused due to reasons other than inflammation of the arteries. Anterior ischemic optic neuropathy is more prevalent as compared to posterior ischemic optic neuropathy. In anterior ischemic optic neuropathy, immediate treatment is required to prevent vision loss in the fellow eye as approximately 50 percent of cases have chances of blindness in another eye within a span of 5 to 10 days without treatment. The symptoms of ischemic optic neuropathy include unilateral, acute and painless visual loss for hours to days. Hypertension, diabetes, and hypercholesterolemia are some of the well-known risk factors associated with ischemic optic neuropathy disease. Other factors include generalized hypoperfusion, sleep apnea, nocturnal hypotension, vasospasm, severe anemia and failure of autoregulation.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/23077

Technological advancements in ischemic optic neuropathy treatment and availability of alternative drugs are anticipated boost the demand for ischemic optic neuropathy treatments over the forecast period.

The global ischemic optic neuropathy treatment market can be segmented on the basis of disease type, treatment type and end user.

On the basis of disease type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of treatment type, the global ischemic optic neuropathy treatment market can be segmented into:

On the basis of end user, the global ischemic optic neuropathy treatment market can be segmented into:

To receive Methodology request here@https://www.persistencemarketresearch.com/methodology/23077

The global ischemic optic neuropathy treatment market is expected to register a significant CAGR over the forecast period. The increasing adoption of recently approved intravitreal implants in the treatment of ophthalmology diseases is anticipated to propel the growth of the ischemic optic neuropathy treatment market over the forecast period. Leading pharmaceutical and drug manufacturing companies from developed countries are substantially investing in R&D, infrastructure and new technologies in ophthalmology therapeutics to capture a market share in the growing burden of eye diseases, which also boosts the growth of the global ischemic optic neuropathy treatment market. With growing awareness towards eye-related complications that lead to blindness, geriatric population and diabetic patients in developed countries, such as the U.S., Russia, and Poland, Germany and Japan are seen to have a proactive approach for treatment related to complications rather than reactive treatment, which also bolsters the growth of the market of ischemic optic neuropathy treatment.

Corticosteroid is the first choice of therapy for patients with ischemic optic neuropathy in prominent countries, such as the U.S., Germany, France, and Russia; however, a majority of patients have developed resistance to anti-VEGF, which leads to the adoption of alternative therapy in patients with ischemic optic neuropathy. This is anticipated to drive the growth of the global ischemic optic neuropathy treatment market in the long run.

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23077

However, medications such as intravitreal injections of anti-VEGF drugs and corticosteroids lead to an instant increase in intraocular pressure, which may lead to severe adverse effects such as conjunctival haemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased and vitreous detachment. This may restrain the growth of the global ischemic optic neuropathy treatment market.

On the basis of regional presence, the global ischemic optic neuropathy treatment market can segmented into five key regions, namely North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa.

North America is a dominant region in the market and contributes a leading share to the global ischemic optic neuropathy treatment market in terms of revenue. The market in the region is expected to register significant growth over the forecast period due to the availability of developed medical infrastructure and treatment facilities in the region. Europe also contributes a moderate share and registered a healthy growth rate in the global ischemic optic neuropathy treatment market. The APEJ region has become a lucrative market for ischemic optic neuropathy treatment and is anticipated to register a significant share over the forecast period, due to the increase in research and development activities along with the growth in medical tourism in the region. Latin America and MEA are in the nascent stage in the global ischemic optic neuropathy treatment market and are expected to register moderate growth over the forecast period.

Some of the market players operating in the ischemic optic neuropathy treatment market include

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
The Ischemic Optic Neuropathy Treatment Market to remain unfazed by the Global Recession - Khabar South Asia

Read More...

Leber’s Hereditary Optic Neuropathy Drug Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – The Market Feed

December 3rd, 2020 11:58 pm

A new research study has been presented by dataintelo offering a comprehensive analysis on the Global Lebers Hereditary Optic Neuropathy Drug Market where user can benefit from the complete market research report with all the required useful information about this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

The Lebers Hereditary Optic Neuropathy Drug Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Lebers Hereditary Optic Neuropathy Drug Market Report with Latest Industry Trends @ https://dataintelo.com/request-sample/?reportId=127623

Major Players Covered in this Report are: Alkeus Pharmaceuticals, Inc.Biovista Inc.GenSight Biologics S.A.Ixchel Pharma, LLCKhondrion BVSpark Therapeutics, Inc.Stealth BioTherapeutics Inc.

Global Lebers Hereditary Optic Neuropathy Drug Market SegmentationThis market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level. Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:ElamipretideGS-011IXC-201KH-176Others

By Applications:HospitalClinicOthers

To get Incredible Discounts on this Premium Report, Click Here @ https://dataintelo.com/ask-for-discount/?reportId=127623

Global Lebers Hereditary Optic Neuropathy Drug Market Regions and Countries Level AnalysisRegional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Lebers Hereditary Optic Neuropathy Drug on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Lebers Hereditary Optic Neuropathy Drug sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted. This study provides Lebers Hereditary Optic Neuropathy Drug sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Make an Inquiry of this Report @ https://dataintelo.com/enquiry-before-buying/?reportId=127623

Why Choose Us:

Table of Contents1. Executive Summary2. Assumptions and Acronyms Used3. Research Methodology4. Market Overview5. Global Market Analysis and Forecast, by Types6. Global Market Analysis and Forecast, by Applications7. Global Market Analysis and Forecast, by Regions8. North America Market Analysis and Forecast9. Latin America Market Analysis and Forecast10. Europe Market Analysis and Forecast11. Asia Pacific Market Analysis and Forecast12. Middle East & Africa Market Analysis and Forecast13. Competition Landscape

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:

Name: Alex Mathews

Address: 500 East E Street, Ontario,

CA 91764, United States.

Phone No: USA: +1 909 545 6473

Email:[emailprotected]

Website:https://dataintelo.com

Read the rest here:
Leber's Hereditary Optic Neuropathy Drug Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - The Market Feed

Read More...

Gene therapy gives man with sickle cell disease the chance for a better future – Science Codex

December 3rd, 2020 11:56 pm

For Evie Junior, living with sickle cell disease has been like running a marathon.

"But it's a marathon where as you keep going, the trail gets rockier and then you lose your shoes," the 27-year-old said. "It gets harder as you get older. Things start to fail and all you can think about is how much worse it's going to get down the road."

In sickle cell disease, a genetic mutation causes the blood-forming stem cells -- which give rise to all blood and immune cells -- to produce hard, sickle-shaped red blood cells. These misshapen cells die early, leaving an insufficient number of red blood cells to carry oxygen throughout the body. Because of their sickle shape, these cells also get stuck in blood vessels, blocking blood flow and resulting in excruciating bouts of pain that come on with no warning and can leave patients hospitalized for days.

The disease affects 100,000 people in the United States and millions around the world, the majority of whom are of African or Hispanic descent. It can ultimately lead to strokes, organ damage and early death.

As a child growing up in the Bronx, New York, Junior had to have his gall bladder and spleen removed due to complications from the disease, but he refused to let his condition limit him. He played football, basketball and baseball during the day, even though on some nights he experienced pain crises so severe he couldn't walk.

"It was just really routine if I had a sickle cell crisis," he said. "Going to the emergency room, staying in the hospital, coming out in a few days and then getting back to normal life."

'I want to create a better future'

When he was 24 and living in Portland, Oregon, Junior began working as an emergency medical technician. He adopted the same mentality -- trying to treat his pain episodes the best he could, and hoping they would resolve overnight so he could get back to work. Around that time, though, the crises became harder to manage. He developed pericarditis, an inflammation in the layers of tissue around his heart, and needed six weeks to recover.

"The big worry with sickle cell disease is that you're going to die young from some type of complications or damage to your organs," he said. "In the last couple of years, I've been seeing that slowly happen to me and I can only suspect that it's going to keep getting worse. I want to create a better future for myself."

In July 2019, in pursuit of that future, Junior enrolled in a clinical trial for an experimental stem cell gene therapy for sickle cell disease. The study is led by UCLA Broad Stem Cell Research Center physician-scientists Dr. Donald Kohn and Dr. Gary Schiller and funded by the California Institute for Regenerative Medicine.

The therapy, developed by Kohn over the past 10 years, is intended to correct the mutation in patients' blood-forming stem cells to allow them to produce healthy red blood cells. Kohn has already applied the same concept to successfully treat several immune system deficiencies, including a cure for a form of severe combined immune deficiency, also known as bubble baby disease.

But sickle cell disease has proven more difficult to treat with gene therapy than those other conditions. Junior volunteered for the trial knowing there was a chance the therapy wouldn't cure him.

"Even if it doesn't work for me, I'm hoping that it can be a cure later down the road for millions of people," he said.

In July 2020, Junior received an infusion of his own blood-forming stem cells that had been genetically modified to overcome the mutation that causes his disease.

"The goal of this treatment is to give him a future, let him plan for college, family or whatever he wants without worrying about getting hospitalized because of another pain crisis," said Kohn, a distinguished professor of microbiology, immunology and molecular genetics, pediatrics, and molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.

Reason for optimism

Three months after his treatment, blood tests indicated that 70% of Junior's blood stem cells had the new corrected gene. Kohn and Schiller estimate that even a 20% correction would be enough to prevent future sickle cell complications. Junior said he hasn't had a pain crisis since undergoing the treatment and he has more energy and feels out of breath less often.

"I noticed a big difference in my cardiovascular endurance in general -- even going for a light jog with my dogs, I could feel it," he said.

Junior and his doctors are cautiously optimistic about the results.

"It's too early to declare victory, but it's looking quite promising at this point," Kohn said. "Once we're at six months to a year, if it looks like it does now, I'll feel very comfortable that he's likely to have a permanent benefit."

After a lifetime of dealing with the unwelcome surprises of the disease, Junior is even more cautious than his doctors. But as the weeks pass, he's slowly allowing a glimmer of hope that he could soon be someone who used to have sickle cell disease. For him, that hope feels like "a burst of happiness" that's followed by thoughts of all the things he could do with a healthy future: pursue his dream of becoming a firefighter, get married and start a family.

"I want to be present in my kids' lives, so I've always said I'm not going to have kids unless I can get this cured," he said. "But if this works, it means I could start a family one day."

Read more from the original source:
Gene therapy gives man with sickle cell disease the chance for a better future - Science Codex

Read More...

Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous…

December 3rd, 2020 11:56 pm

This article was originally published here

J Vasc Interv Radiol. 2020 Nov 25:S1051-0443(20)30769-7. doi: 10.1016/j.jvir.2020.09.003. Online ahead of print.

ABSTRACT

PURPOSE: To evaluate safety and efficacy of angiogenesis induced by intraarterial autologous bone marrow-derived stem cell (BMSC) injection in patients with severe peripheral arterial disease (PAD).

MATERIALS AND METHODS: Eighty-one patients with severe PAD (77 men), including 56 with critical limb ischemia (CLI) and 25 with severe claudication, were randomized to receive sham injection (group A) or intraarterial BMSC injection at the site of occlusion (group B). Primary endpoints included improvement in ankle-brachial index (ABI) of > 0.1 and transcutaneous pressure of oxygen (TcPO2) of > 15% at mid- and lower foot at 6 mo. Secondary endpoints included relief from rest pain, > 30% reduction in ulcer size, and reduction in major amputation in patients with CLI and > 50% improvement in pain-free walking distance in patients with severe claudication.

RESULTS: Technical success was achieved in all patients, without complications. At 6 mo, group B showed more improvements in ABI of > 0.1 (35 of 41 [85.37%] vs 13 of 40 [32.50%]; P < .0001) and TcPO2 of > 15% at the midfoot (35 of 41 [85.37%] vs 17 of 40 [42.50%]; P = .0001] and lower foot (37 of 41 [90.24%] vs 19 of 40 [47.50%]; P < .0001). No patients with CLI underwent major amputation in group B, compared with 4 in group A (P = .0390). No significant difference was observed in relief from rest pain or > 30% reduction in ulcer size among patients with CLI or in > 50% improvement in pain-free walking distance among patients with severe claudication.

CONCLUSIONS: Intraarterial delivery of autologous BMSCs is safe and effective in the management of severe PAD.

PMID:33248918 | DOI:10.1016/j.jvir.2020.09.003

Read more here:
Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Therapeutic Efficacy of Angiogenesis Induced by Intraarterial Autologous...

Read More...

Coronavirus Updates: The Latest Treatments and Vaccines – GovTech

December 3rd, 2020 11:56 pm

(TNS) - Scientists at Bay Area universities, laboratories, biotechnology companies and drug manufacturers are fashioning drug concoctions out of blood plasma, chimpanzee viruses and cells taken from bone marrow in the race to rid the world of COVID-19.

The microbial treasure hunt is not just to find a cure which may not be possible but to control the debilitating health problems caused by the coronavirus.

Major progress has been made this year. The antiviral drug remdesivir, produced in Foster City, has improved recovery times, and the steroid dexamethasone has cut the number of deaths in severely ill patients.

What follows is a list of some of the most promising medications and vaccines with ties to the Bay Area:

Antibodies

and Immunity

Mesenchymal stem cells / UCSF and UC Davis Medical Center:

UCSF Dr. Michael Matthay is leading a study of whether a kind of stem cell found in bone marrow can help critically ill patients with severe respiratory failure, known as ARDS. Matthay hopes the stem cells can help reduce the inflammation associated with some of ARDS' most dire respiratory symptoms, and help patients' lungs recover.

In all, 120 patients are being enrolled at UCSF Medical Center, Zuckerberg San Francisco General Hospital, the UC Davis Medical Center in Sacramento and hospitals in Oregon and Texas. He said the trial, which includes a small number of ARDS patients who don't have COVID-19, should have results by summer or fall 2021. So far, 28 patients are enrolled in San Francisco.

Lambda-interferon / Stanford University:

Lambda-interferon is a manufactured version of a naturally occurring protein that had been used to treat hepatitis, and researchers hoped it would help patients in the early stages of COVID-19.

Stanford researchers completed their trial of lambda-interferon and found that it did not boost the immune system response to coronavirus infections.

"That trial did not find any difference in outcomes between the treatment and placebo," said Yvonne Maldonado, chief of pediatric infectious diseases at Lucile Packard Children's Hospital at Stanford, where 120 patients were enrolled in the trial. "It didn't work."

Antiviral drugs

Remdesivir / Gilead Sciences ( Foster City):

Remdesivir, once conceived as a potential treatment for Ebola, was approved by the Food and Drug Administration in October for use on hospitalized COVID-19 patients.

Trademarked under the name Veklury, the drug interferes with the process through which the virus replicates itself. It was one of the drugs given to President Trump and has been used regularly in hospitals under what is known as an emergency use authorization.

It was approved after three clinical trials showed hospitalized coronavirus patients who received remdesivir recovered five days faster on average than those who received a placebo. Patients who required oxygen recovered seven days faster, according to the studies.

Gilead now plans to conduct clinical trials to see how remdesivir works on pediatric patients, from newborns to teenagers, with moderate to severe COVID-19 symptoms. Remdesivir is also being studied with steroids and other drugs to see if it works better as part of a medicinal cocktail. An inhalable form of the drug is also being developed.

Favipiravir / Fujifilm Toyama Chemical ( Stanford University):

This antiviral drug, developed in 2014 by a subsidiary of the Japanese film company to treat influenza, is undergoing numerous clinical studies worldwide, including a trial involving 180 patients at Stanford University.

Stanford epidemiologists are testing favipiravir to see if it prevents the coronavirus from replicating in human cells, halts the shedding of the virus and reduces the severity of infection. Unlike remdesivir, it can be administered orally, so it can be used to treat patients early in the disease, before hospitalization is necessary.

The Stanford study has so far enrolled about 90 patients, who are given the drug within 72 hours of when they were first diagnosed with COVID-19. Half of them get a placebo. People can enroll by emailing treatcovid@stanford.edu.

Monoclonal antibodies

REGN-COV2 / Regeneron Pharmaceuticals / Stanford School of Medicine:

The REGN-COV2 cocktail is the same one Trump received, and Stanford is one of dozens of locations nationwide where clinical trials are being held. Two separate trials are under way at Stanford one for hospitalized patients, the other for outpatients. A third trial is about to begin for people who aren't sick but are in contact with carriers of the virus.

Regeneron halted testing on severely ill patients requiring high-flow oxygen or mechanical ventilation after the independent Data and Safety Monitoring Board determined that the drug was unlikely to help them.

The drug is a combination of two monoclonal antibodies lab-made clones of the antibodies produced naturally in people who have recovered from COVID-19. The antibodies bind to the virus' spike protein and block the virus' ability to enter cells.

Dr. Aruna Subramanian, professor of infectious diseases at Stanford and lead investigator for the inpatient trial, said the 21 hospitalized patients in the study receive a high dose like Trump, a lower dose or a placebo. Subramanian plans to expand the inpatient trial to 45 patients. The outpatient study has enrolled a little more than 40 of the 60 patients researchers intend to sign up.

"There's enough promising evidence that it helps people early in the infection," Subramanian said. "What we don't know is whether it helps people who are pretty sick but not critically ill."

Bamlanivimab / Eli Lilly / Stanford and UCSF:

Stanford and UCSF are testing the Eli Lilly monoclonal antibodies on outpatients after the pharmaceutical company halted trials on hospitalized COVID-19 patients because of adverse results.

Dr. Andra Blomkalns, chair of emergency medicine at Stanford and the lead in the Eli Lilly outpatient trial, said she is now enrolling older people with comorbidities like heart disease, chronic lung disease, a history of strokes and severe obesity shortly after they test positive.

The hypothesis is that the bamlanivimab monotherapy, which is very similar to the Regeneron monoclonals, might work best early in the infection. Although about 400 patients have been enrolled in the Lilly phase 3 trials nationwide, to date fewer than 10 have been enrolled at Stanford and UCSF.

Matthay, who headed up the Lilly monoclonal study with LY-CoV555 at UCSF, said the cancellation of this inpatient trial was disappointing, but "just because this one did not work, doesn't mean another one won't work for hospitalized patients."

Blomkalns said the testing criteria has been changing. She expects the outpatient trial to open soon to adolescents ages 12 and up to determine whether the drug can be used as a preventive.

Designer monoclonal antibodies / Vir Biotechnology, San Francisco:

Scientists at Vir are studying several types of monoclonal antibodies, including a type engineered to activate T cells, which can search out and destroy cells infected with the coronavirus. A study published in the journal Nature in October found that monoclonals, modified to bind with certain receptors, stimulated T cells and improved the human immune response.

"By observing and learning from our body's powerful natural defenses, we have discovered how to maximize the capacity of antibodies through the amplification of key characteristics that may enable more effective treatments for viral diseases," said Herbert Virgin, the chief scientific officer at Vir and co-author of the study.

A similarly modified monoclonal antibody, leronlimab, is being studied in coronavirus clinical trials by its Washington state drugmaker, CytoDyn, which has developed drugs to treat HIV. The company's chief medical officer is in San Francisco, and the company that does laboratory tests of leronlimab is in San Carlos.

Anti-inflammatory drugs

Colchicine / UCSF ( San Francisco and New York):

The anti-inflammatory drug commonly used to treat gout flare-ups is being studied by scientists at UCSF and New York University. The drug short-circuits inflammation by decreasing the body's production of certain proteins, and researchers hope that it will reduce lung complications and prevent deaths from COVID-19.

Preliminary results from a clinical trial found that "Colchicine can be effective in reducing systemic symptoms of COVID-19 by inhibiting inflammatory biomarkers."

Selinexor / Kaiser Permanente:

Kaiser hospitals in San Francisco, Oakland and Sacramento are studying selinexor, an anticancer drug that blocks a key protein in the cellular machinery for DNA processing. Preliminary findings during the trials indicated that low doses of selinexor helped hospitalized patients with severe COVID-19. The drug has both antiviral and anti-inflammatory properties, and it's administered orally, according to Kaiser's Dr. Jacek Skarbinski.

Vaccines

VXA-COV2-1 / Vaxart, South San Francisco:

The biotechnology company Vaxart is testing VXA-COV2-1, the only potential vaccine in pill form. It uses the genetic code of the coronavirus to trigger a defensive response in mucous membranes. The hope is that the newly fortified membranes will prevent the virus from entering the body.

"It's the only vaccine (candidate) that activates the first line of defense, which is the mucosa," said Andrei Floroiu, Vaxart's chief executive. He said intravenous vaccines kill the virus after it is inside the body, but this one stops it beforehand.

View original post here:
Coronavirus Updates: The Latest Treatments and Vaccines - GovTech

Read More...

Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 – The Market Feed

December 3rd, 2020 11:56 pm

Graft Versus Host Disease (GVHD) Epidemiology

According to the National Cancer Institute (NCI), Graft versus host disease (GVHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

GVHDhas two types Acute GVHDand Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects the liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucus or saliva.

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

DelveInsights Graft Versus Host Disease (GVHD) Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease (GVHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.The DelveInsight Graft Versus Host Disease (GVHD) epidemiology report gives a thorough understanding of the Graft Versus Host Disease (GVHD) disease symptoms and causes, along with the risk factors, diagnosis, pathophysiology associated with the disease, and. It also provides treatment algorithms and treatment guidelines for Graft Versus Host Disease (GVHD) in the US, Europe, and Japan. The report covers the detailed information of the Graft Versus Host Disease (GVHD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Key Highlights Of The Report

As per a study by Elgaz S. et al., (2019), GVHDoccurs in 3050% of recipients and 14% of all patients suffer severe GVHDgrades 34. Chronic GVHDaffects 3070% of patients receiving allo-SCT.

As per a study by Jacobsohn and Vogelsang (n.d.) titled Acute graft versus host disease, in the United States, approximately 5,500 patients/year can develop acute GVHD and in 2003, the incidence of grade II-IV acute GVHD was roughly 3550%.

As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.

Graft Versus Host Disease (GVHD) Epidemiology

Scope of the Report

Key Benefit of Graft Versus Host Disease (GVHD) Epidemiology Report

The Graft Versus Host Disease (GVHD) Epidemiology report will allow the user to

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Table of Contents

*The table of contents is not exhaustive; will be provided in the final report

Related ReportsGraft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030DelveInsight s Graft versus host disease (GVHD) Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Graft versus host disease (GVHD) Pipeline Insights, 2020Graft versus host disease (GVHD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market.

About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact usShruti Thakur[emailprotected]+91-9650213330https://www.delveinsight.com/LinkedIn | Facebook | TwitterGraft Versus Host Disease (GVHD) Epidemiology Report:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Here is the original post:
Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed

Read More...

Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes – India Education Diary

December 3rd, 2020 11:56 pm

Ottawa: There are more than 300,000 Canadians living with type 1 diabetes (T1D), an autoimmune disease with no known cause or cure, resulting in the dysfunction, damage or loss of pancreatic beta cells that produce insulin in our bodies. People with T1D must treat themselves with insulin several times per day to keep their blood glucose levels normal, and despite their best efforts, they often experience serious, and even life-threatening, complications.

To mark the end of Diabetes Awareness Month, Sonia Sidhu, Member of Parliament for Brampton South, on behalf of the Honourable Patty Hajdu, Minister of Health, announced an investment of $6 million through the CIHR-JDRF Partnership to Defeat Diabetes for two Canadian research teams to accelerate the development of stem cell-based therapies for the treatment of T1D.

Stem cells show great promise as a source of insulin-producing cells that could be transplanted to provide a new source of insulin, to replace dysfunctional, damaged or lost pancreatic beta cells. Canada has a remarkable legacy in leading discoveries in this area. Stem cells were discovered in Toronto in 1961, and in 2000, a team in Edmonton were the first to pioneer transplantation of pancreatic islets (the part of the pancreas that contains insulin-producing cells). These achievements represent important steps toward a treatment that will allow people with T1D to live healthy lives without daily insulin injections.

The research teams are led by Dr. Maria Cristina Nostro at the University Health Network and the University of Toronto and Dr. Francis Lynn at the BC Childrens Hospital Research Institute and the University of British Columbia. The teams will build on Canadas demonstrated research excellence and leadership in clinical islet transplantation, stem cell biology, diabetes, immunology and genetic engineering to accelerate stem cell-based therapies for T1D. They will work in collaboration with other Canadian researchers to tackle some of the biggest scientific challenges that impede our progress in this area and move us closer to a future where people with T1D will no longer rely on insulin therapy.

This funding was provided by the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), and JDRF Canada, through the CIHR-JDRF Partnership to Defeat Diabetes established in 2017. Each partner will invest $3 million over five years. This investment is part of a large research initiative, 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, funded by CIHR and partners. This initiative commemorates the 100th anniversary of the discovery of insulin to be marked in 2021a discovery that changed the lives of millions of Canadians and people around the world and won researchers Sir Frederick Banting and John Macleod the Nobel Prize in Physiology or Medicine.

See the original post:
Government of Canada and JDRF Canada announce new research funding to accelerate stem cell-based therapies for type 1 diabetes - India Education Diary

Read More...

Help to alleviate the nagging, debilitating pain of arthritis – OrilliaMatters

December 3rd, 2020 11:55 pm

Thursday evening's Our Health event gives local residents a chance to get answers to their questions regarding the disease

Getting answers about a debilitating medical condition can sometimes be a challenge.

Thats why Thursday's Our Health session will explore the toll arthritis exerts on area residents, who might be having trouble these days getting out of a chair or walking up the stairs at home.

It's serious, said Dr. Olivia Cheng, an orthopaedic surgeon at Georgian Bay General Hospital and Collingwood General and Marine Hospital.

One in five Canadians live every day with arthritis and there is no cure. Arthritis is a collection of conditions affecting joints and other tissues. It causes pain, restricts mobility and diminishes quality of life.

Entitled Living your Best Life with Arthritis, the live, virtual event goes Thursday at 7:30 p.m.Moderated by retired physician Keith Rose, Cheng and other panelists will discuss how residents can manage their symptoms and improve their quality of life through therapeutic exercise, physical activity and joint-replacement surgery.

According to the Canadian Arthritis Society, arthritis affects about 6 million Canadians. There are many types of arthritis, including non-inflammatory osteoarthritis or inflammatory such as rheumatoid arthritis.

Osteoarthritis affects one in six Canadians. It is a chronic disease which causes pain, stiffness, swelling and decreased movement in the hips, knees, fingers, toes or spine resulting from the bodys failed attempt to repair damaged joint tissue.

When we look at the impact of arthritis, we need to take into consideration other musculoskeletal disorders affecting the joints, ligaments, tendons, bones, etc., Cheng said. All of these can cause pain and functional limitations.

Arthritis is often written off as just arthritis, and a natural part of aging, however, the mortality, morbidity burden of arthritis and the economic cost of arthritis has been underestimated. As a result, people often live with arthritis for years before receiving appropriate help.

Cheng said its important to learn about the symptoms of arthritis and to seek appropriate help.

Early diagnosis and treatment of the illness can prevent or delay progression of the disease, she said. Also, managing the symptoms of arthritis can help you live a better life. The natural history of arthritis is that this disease will flare up intermittently with an overall progression over time.

According to Cheng, risk factors for arthritis that you can control include being overweight, previous injury to the joint and smoking with factors beyond ones control ranging from age, gender since its more common in women and genetics since inflammatory arthritis often runs in the family.

Once you are diagnosed with arthritis, then you can address the factors that are within your control, she said. These include strengthening exercises to help protect and unload your joint.

Keeping your weight healthy will help decrease the mechanical load on your joint and decrease the inflammatory factors in your body. Environmental factors such as eating food that minimizes inflammationand stopsmoking are also important.

For inflammatory arthritis such as rheumatoid arthritis, there are many advances in medications that can help control the disease progression.

Cheng said shes often asked about the wait list for total joint-replacement surgeries.

There is an increase in the prevalence of arthritis in Canada, the static trend in rates of joint-replacement procedures suggests that the system may be operating at capacity, she said. In our region, patients with arthritis are referred by their family doctors to a central intake clinic where they are assessed by an advanced-practice physiotherapist.

Patients who are candidates for surgery are then referred to either their preferred or next available surgeon. The limiting factors on the ability for us to perform joint-replacement surgery include the number of joints we are allocated by the health ministry, operating room availabilityand hospital capacity.

Thursdays event will be broadcast on Rogers TV channel 53 (Midland, Tay and Penetanguishene only). For those with smart phones, tablets or computers with a Wi-Fi connection, you can view online. Questions can be submitted to mccjared@mcc.com.

Originally posted here:
Help to alleviate the nagging, debilitating pain of arthritis - OrilliaMatters

Read More...

Page 279«..1020..278279280281..290300..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick